Gefapixant
Published , updated
Unassigned
New Medicines
Chronic cough, including cough with Idiopathic Pulmonary Fibrosis
Information
New molecular entity
Merck Sharp & Dohme (MSD)
Merck & Co (name used in US for MSD)
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Purinergic P2X3 receptor antagonist; P2X3 receptors are expressed in afferent neurones that transmit pain perception.
Chronic cough, most commonly defined as cough lasting 3 months or more, is common; a reasonably robust estimate suggests that global prevalence is about 9.6% and European prevalence about 12.7% [2]. There are no effective drug treatments with an acceptable therapeutic ratio [3].
Chronic cough, including cough with Idiopathic Pulmonary Fibrosis
Oral
Further information
Yes
To be confirmed